IngeniumAI is a University of Bath and Royal United Hospitals Bath NHS Trust spin-out on a mission to transform the diagnosis of rare but serious diseases. Our core asset is a software platform that uses AI and other advanced techniques to analyse routinely collected medical imaging, unlocking insights that are typically overlooked until it’s too late. By identifying early signs of uncommon but deadly conditions, our technology empowers clinicians to make faster, more accurate diagnoses, improving patient outcomes while reducing strain on the healthcare system.
Our first product, PHAST®, focuses on pulmonary hypertension, a cardio-respiratory disease that is notoriously difficult to detect early. Our prototype outperforms specialist radiologists and has the potential to cut diagnosis time from years to weeks. We’re now preparing for regulatory submission, with support from Innovate UK funding and schemes including CPI MARRS, Imperial College’s Healthcare Technologies Capability Connector, and the RADIANT-CERSI Innovation Support Programme.
What sets us apart is our deep integration of clinical and technical expertise: the founding team includes AI researchers and NHS clinicians, and we benefit from direct access to annotated datasets, implementation feedback, and strong healthcare networks. Our cloud-based platform is designed to scale, enabling us to expand into additional disease areas over time.
We’re actively seeking corporate partners, customers, investors, and collaborators to support our growth as we bring advanced diagnostics closer to patients.
